These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8394450)

  • 21. Phenotypic characterization of antigenic hybrids of poliovirus.
    Murdin AD; Kameda A; Murray MG; Wimmer E
    Microb Pathog; 1991 Jan; 10(1):39-45. PubMed ID: 1649944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
    Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
    J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular basis of antigenic structures of poliovirus: implications for their evolution during morphogenesis.
    Wiegers K; Dernick R
    J Virol; 1992 Jul; 66(7):4597-600. PubMed ID: 1376371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
    Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
    J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
    Taniguchi K; Urasawa S
    Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.
    Icenogle J; Gilbert SF; Grieves J; Anderegg J; Rueckert R
    Virology; 1981 Nov; 115(1):211-5. PubMed ID: 6270899
    [No Abstract]   [Full Text] [Related]  

  • 30. Preliminary studies on antigenic variation of poliovirus using neutralizing monoclonal antibodies.
    Guo R; Tang EH; Wang H; Yang XF; Liu MY; Qin HX; Li QH; Zhuang JY; Liu KM
    J Gen Virol; 1987 Apr; 68 ( Pt 4)():989-94. PubMed ID: 3033136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poliovirus neutralization and the percentage law. Brief report.
    Brioen P; Boeyé A
    Arch Virol; 1985; 83(1-2):105-11. PubMed ID: 2982345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
    Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
    Evans DM; Minor PD; Schild GS; Almond JW
    Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.
    Ferguson M; Schild GC; Minor PD; Yates PJ; Spitz M
    J Gen Virol; 1981 Jun; 54(Pt 2):437-42. PubMed ID: 6270261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II.
    Murdin AD; Wimmer E
    J Virol; 1989 Dec; 63(12):5251-7. PubMed ID: 2479772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
    Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
    J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.